Metformin & Cephalexin Interaction

Metformin and cephalexin have a pharmacokinetically documented but clinically modest interaction. Cephalexin (a first-generation cephalosporin) competes with metformin for renal tubular secretion via the OCT2/MATE transporters. This can reduce metformin renal clearance and increase metformin plasma concentrations. The interaction is generally mild and does not require routine dose adjustment in patients with normal renal function.

Metformin is eliminated renally via active tubular secretion through organic cation transporters OCT2 (uptake into tubular cells) and MATE1/MATE2-K (efflux into urine). Cephalexin is also secreted by these same renal tubular transporters. Competition for OCT2/MATE-mediated secretion can reduce metformin elimination, increasing its area under the curve (AUC) by approximately 24% according to pharmacokinetic studies. This increases metformin exposure and, theoretically, lactic acidosis risk — although lactic acidosis is very rare with therapeutic metformin doses.

A pharmacokinetic study by Somogyi et al. documented a 34% increase in metformin AUC when cephalexin was co-administered. However, for short-term antibiotic courses in patients with normal renal function, the clinical significance is low. Patients with pre-existing renal impairment are at greater theoretical risk because both drugs depend on renal elimination. Cephalexin courses are typically 7–14 days, limiting cumulative exposure.

No routine dose adjustment is required in patients with normal renal function. In patients with reduced renal function (eGFR 30–60), monitor more closely. Ensure adequate hydration during the antibiotic course. Hold metformin if patient develops acute illness causing dehydration or hemodynamic instability. Resume when clinical status returns to baseline.

Renal function (serum creatinine, eGFR) especially in patients with existing chronic kidney disease. Blood glucose during the antibiotic course (infection itself can raise blood glucose). Signs of lactic acidosis (unusual fatigue, myalgia, nausea, respiratory distress) in high-risk patients.

If a broader or narrower antibiotic spectrum is appropriate, amoxicillin or trimethoprim-sulfamethoxazole may also interact with metformin via the same transporters. Clinically, the interaction with all these agents is modest. No antibiotic substitution is typically warranted based on this interaction alone.